Subcutaneous IgG in immune-mediate diseases: Proposed mechanisms of action and literature review

Autoimmunity Reviews

Volumn 13, Issue 12, 2014, Pages 1182-1188

  Danieli, Maria Giovanna ^a   Gelardi, Chiara ^a   Pedini, Veronica ^a   Moretti, Romina ^a   Gabrielli, Armando ^a   Logullo, Francesco ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Autoimmune disease; Dermatomyositis; Immune mediated disease; Intravenous immunoglobulin; Polymyositis; Subcutaneous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN;

CHRONIC INFLAMMATORY DEMYELINATING NEUROPATHY; DEMYELINATING NEUROPATHY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; HUMAN; IMMUNOPATHOLOGY; MOTOR NEUROPATHY; MYOPATHY; MYOSITIS; NEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; IMMUNOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

ANIMALS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYOSITIS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84908189418     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.018     Document Type: Review

References (57)

1. Bruton O.C. Agammaglobulinemia. Pediatrics 1952, 9(6):722-728.
2. Abolhassani H., Sadaghiani M.S., Aghamohammadi A., Ochs H.D., Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulinin treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012, 32(6):1180-1192.
3. Orange J.S., Belohradsky B.H., Berger M., Borte M., Hagan J., Jolles S., et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012, 169(2):172-181.
4. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 11(11):792-794.
5. Melzer N., Meuth S.G. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol 2014, 175(3):359-372.
6. Lo E., Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev 2014, 13(4-5):577-583.
7. Ruffatti A., Marson P., Svaluto-Moreolo G., Marozio L., Tibaldi M., Favaro M., et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev 2013, 12(7):768-773.
8. Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013, 12(11):1085-1090.
9. Saadoun D., Bodaghi B., Bienvenu B., Wechsler B., Sene D., Trad S., et al. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013, 12(7):774-783.
10. Goebel A., Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 2013, 12(6):682-686.
11. Wang Y., Wang W., Gong F., Fu S., Zhang Q., Hu J., et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 2013, 65(3):805-814.
12. Rogosnitzky M., Danks R., Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev 2012, 12(2):275-280.
13. Eftimov F., Winer J.B., Vermeulen M., de Haan R., van Schaik I.N. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009, 1. [CD001797].
14. van Schaik I.N., van den Berg L.H., de Haan R., Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005, 2. [CD004429].
15. Hughes R.A., Dalakas M.C., Cornblath D.R., Latov N., Weksler M.E., Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009, 158(Suppl. 1):34-42.
16. Elovaara I., Apostolski S., van Doorn P., Gilhus N.E., Hietaharju A., Honkaniemi J., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008, 15:893-908.
17. Carstens P.O., Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 2014, 175(3):349-358.
18. Miescher S.M., Käsermann F. The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease. Autoimmun Rev 2013, 12(6):639-642.
19. Misbah S., Sturzenegger M.H., Borte M., Shapiro R.S., Wasserman R.L., Berger M., et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009 Dec, 158(Suppl. 1):51-59.
20. Rajabally Y.A. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. J Neurol Neurosurg Psychiatry 2014, 85:631-637.
21. Danieli M.G., Pettinari L., Moretti R., Logullo F., Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011, 10:144-149.
22. Kaveri S.V., Maddur M.S., Hegde P., Lacroix-Desmazes S., Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011 Jun, 164(Suppl. 2):2-5.
23. Katz U., Shoenfeld Y., Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases. Curr Pharm Des 2011, 17(29):3166-3175.
24. Seite J.F., Shoenfeld Y., Youinou P., Hillion S. What is the contents of the magic draft IVIg?. Autoimmun Rev 2008, 7:435-439.
25. Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy 2014, 6:71-83.
26. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12(3):436-443.
27. Fernandez-Cruz E., Kaveri S.V., Peter H.H., Durandy A., Cantoni N., Quinti I., et al. 6th International Immunoglobulin Symposium: poster presentations. Clin Exp Immunol 2009, 158(Suppl. 1):60-67.
28. Maddur M.S., Hegde P., Sharma M., Kaveri S.V., Bayry J. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells. Autoimmun Rev 2011, 11:154-156.
29. Yokota M., Suzuki K., Tokoyoda K., Meguro K., Hosokawa J., Tanaka S., et al. Roles of mast cells in the pathogenesis of inflammatory myopathy. Arthritis Res Ther 2014, 17;16(2):R72.
30. Blank M., Bashi T., Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol 2014, 1060:353-361.
31. Kessel A., Ammuri H., Peri R., Pavlotzky E.R., Blank M., Shoenfeld Y., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007, 179:5571-5575.
32. Trinath J., Hegde P., Sharma M., Maddur M.S., Rabin M., Vallat J.M., et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 2013, 122:1419-1427.
33. Allenbach Y., Solly S., Grégoire S., Dubourg O., Salomon B., Butler-Browne G., et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009, 174:989-998.
34. Chapman J., Shoenfeld Y. Chronic inflammatory demyelinating polyradiculoneuropathy: revisiting the role of intravenous immmunoglobulins. Isr Med Assoc J 2013, 15:293-294.
35. Kieseier B.C., Tani M., Mahad D., Oka N., Ho T., Woodroofe N., et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002, 125:823-834.
36. Yan W.X., Taylor J., Andrias-Kauba S., Pollard J.D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000, 47:765-775.
37. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol 2013, 13:176-189.
38. von Gunten S., Shoenfeld Y., Blank M., Branch D.R., Vassilev T., Käsermann F., et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol 2014, 14:349.
39. Zhang G., Lopez P.H., Li C.Y., Mehta N.R., Griffin J.W., Schnaar R.L., et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004, 127:1085-1100.
40. Iijima M., Tomita M., Morozumi S., Kawagashira Y., Nakamura T., Koike H., et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 2009, 73:1348-1352.
41. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
42. Danieli M.G., Moretti R., Gambini S., Paolini L., Gabrielli A. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 2014, 33:531-536.
43. Schleinitz N., Jean E., Benarous L., Mazodier K., Figarella-Branger D., et al. Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?. Clin Rheumatol 2008, 27:1067-1068.
44. Pars K., Garde N., Skripuletz T., Pul R., Dengler R., Stangel M. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 2013, 48:838-839.
45. Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008, 7:136-144.
46. Léger J.M., De Bleecker J.L., Sommer C., Robberecht W., Saarela M., Kamienowski J., et al. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst 2013, 18:130-140.
47. Nobile-Orazio E., Cocito D., Jann S., Uncini A., Beghi E., Messina P., et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012, 11:493-502.
48. Markvardsen L.H., Debost J.C., Harbo T., Sindrup S.H., Andersen H., Christiansen I., et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013, 20:836-842.
49. Lee D.H., Linker R.A., Paulus W., Schneider-Gold C., Chan A., Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008, 37:406-409.
50. Cocito D., Serra G., Falcone Y., Paolasso I. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 2011, 16:150-152.
51. Köller H., Schroeter M., Feischen H., Hartung H.P., Kieseier B.C. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006, 253:1505-1506.
52. Misbah S.A., Baumann A., Fazio R., Dacci P., Schmidt D.S., Burton J., et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011, 16:92-97.
53. Eftimov F., Vermeulen M., de Haan R.J., van den Berg L.H., van Schaik I.N. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009, 14:93-100.
54. Harbo T., Andersen H., Hess A., Hansen K., Sindrup S.H., Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009, 16:631-638.
55. Harbo T., Andersen H., Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010, 75(15):1377-1380.
56. Dacci P., Riva N., Scarlato M., Andresen I., Schmidt D., Comi G., et al. Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol Sci 2010, 31(6):829-831.
57. Bayas A., Gold R., Naumann M. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. J Neurol Sci 2013, 324(1-2):53-56.